Neovacs SA Announces Capital Reduction and Share Dilution

Neovacs SA (FR:ALNEV) has released an update.

Neovacs SA, a French biopharmaceutical company, has announced a capital reduction due to losses, which involves decreasing the nominal value of its shares from 0.0005 euro to 0.0001 euro. Following the decision of its Board of Directors, the overall share capital is reduced accordingly, affecting the equity per share for investors. The company warns of potential significant share price volatility and dilution risk due to financing operations with European High Growth Opportunities Securitization Fund and a trust arrangement.

For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.